Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,683 stopped studies mapped to Malignant Thoracic Neoplasm and descendants · 90% state a reason
Over the 1,683 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… | Phase 2 / Phase 3 | suspended | May 27, 2020 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With… | Phase 1 / Phase 2 | suspended | Dec 8, 2022 | National Cancer Institute (NCI) | Revisions to eligibility/design being made prior to enrollment of first participants. | Enrollment / accrual |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… | Phase 1 / Phase 2 | suspended | Nov 19, 2024 | National Cancer Institute (NCI) | Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody… | Enrollment / accrual |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | Phase 2 | terminated | May 28, 2020 | Centre hospitalier de l'Université de Montréal (CHUM) | Poor accrual | Enrollment / accrual |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression… | Phase 2 | terminated | Apr 11, 2025 | Shanghai Junshi Bioscience Co., Ltd. | The research and development strategy was adjusted, so the research was suspended | Sponsor / business decision |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated…(G360-IIT) | Phase 2 | terminated | Feb 6, 2023 | Hackensack Meridian Health | Slow Accrual | Enrollment / accrual |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT03891615 | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | Phase 1 | terminated | Mar 27, 2019 | Massachusetts General Hospital | Slow accrual. | Enrollment / accrual |
| NCT01720186 | Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions…(SPI COHERENCE) | N/A | terminated | Nov 2, 2012 | Institut Claudius Regaud | not stated | Not stated |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell… | Phase 1 | suspended | Sep 27, 2024 | Dwight Owen | Pending ICF update | Other (stated, no rule matched) |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475)… | Phase 3 | terminated | Feb 4, 2021 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05937074 | Metabolic Response to Food in Lung Cancer(METRIC) | — | terminated | Jul 10, 2023 | Pennington Biomedical Research Center | Poor accrual. | Enrollment / accrual |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory,… | Phase 2 | withdrawn | Apr 24, 2025 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… | Phase 3 | terminated | Feb 7, 2022 | Merck Sharp & Dohme LLC | MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support… | Efficacy / futility |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Aug 6, 2021 | Suzhou Junjing BioSciences Co., Ltd. | The study was stopped because of a change in the study strategy | Sponsor / business decision |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Phase 2 | suspended | Aug 28, 2023 | City of Hope Medical Center | Budget Issue | Funding |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | Phase 3 | terminated | May 2, 2014 | ETOP IBCSG Partners Foundation | Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a… | Enrollment / accrual |
| NCT04926662 | Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening… | — | suspended | Jun 15, 2021 | Dartmouth-Hitchcock Medical Center | Study is paused while pre-aim 1 work is being done | Other (stated, no rule matched) |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2022 | Novartis Pharmaceuticals | The trial was terminated due to a business decision and not as a result of any safety concerns | Safety / toxicity |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… | Phase 1 / Phase 2 | terminated | May 8, 2024 | GlaxoSmithKline | Operational challenges | Other (stated, no rule matched) |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… | Phase 2 | terminated | Mar 27, 2024 | Memorial Sloan Kettering Cancer Center | Study closed by Amgen due to lack of enrollment | Enrollment / accrual |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or…(PINNACLE) | Phase 3 | suspended | May 18, 2022 | Spectrum Pharmaceuticals, Inc | The study has not enrolled any patients. The study design is under discussion and will likely be… | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Phase 2 | suspended | Jun 10, 2026 | UNC Lineberger Comprehensive Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | Phase 2 | suspended | Apr 26, 2024 | Duke University | Protocol is currently undergoing study design revisions and will re-open after amendment is IRB… | Other (stated, no rule matched) |
| NCT03606070 | Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in…(IMAHTEP) | N/A | terminated | Jul 30, 2018 | Gustave Roussy, Cancer Campus, Grand Paris | Lack of inclusion | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT04017819 | Biodistribution & Pharmacokinetic of Position Emission Tomography (PET)… | Phase 1 | suspended | Jul 12, 2019 | Stanford University | funding | Funding |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic… | — | withdrawn | Jul 20, 2025 | Addario Lung Cancer Medical Institute | Sponsor/Funder decision | Other (stated, no rule matched) |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small… | Phase 2 | terminated | Sep 7, 2018 | Wake Forest University Health Sciences | After interim analysis decided not to move forward with continuing the trial. | Efficacy / futility |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | Phase 1 | withdrawn | Nov 9, 2023 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic… | N/A | suspended | Nov 18, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small…(CT32) | Phase 1 / Phase 2 | terminated | Mar 15, 2021 | Shanghai Junshi Bioscience Co., Ltd. | The company's research strategy was adjusted and the study was terminated | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic… | Phase 2 | terminated | Sep 11, 2015 | Celgene | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials